Sales and EBITDA improved significantly year-on-year and sequentially, with revenue up 52% and EBITDA up 56%. Market expansion, new patents, and a strong cash position support a positive outlook, despite regulatory delays and ongoing global uncertainties.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.